Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease

por Guo, Shuling, Booten, Sheri L, Watt, Andrew, Alvarado, Luis, Freier, Susan M, Teckman, Jeffery H, McCaleb, Michael L, Monia, Brett P
Publicado 2014

Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease

por Cansby, Emmelie, Nuñez-Durán, Esther, Magnusson, Elin, Amrutkar, Manoj, Booten, Sheri L., Kulkarni, Nagaraj M., Svensson, L. Thomas, Borén, Jan, Marschall, Hanns-Ulrich, Aghajan, Mariam, Mahlapuu, Margit
Publicado 2018

Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice

por Nuñez‐Durán, Esther, Aghajan, Mariam, Amrutkar, Manoj, Sütt, Silva, Cansby, Emmelie, Booten, Sheri L., Watt, Andrew, Ståhlman, Marcus, Stefan, Norbert, Häring, Hans‐Ulrich, Staiger, Harald, Borén, Jan, Marschall, Hanns‐Ulrich, Mahlapuu, Margit
Publicado 2017

Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice

por Prakash, Thazha P., Graham, Mark J., Yu, Jinghua, Carty, Rick, Low, Audrey, Chappell, Alfred, Schmidt, Karsten, Zhao, Chenguang, Aghajan, Mariam, Murray, Heather F., Riney, Stan, Booten, Sheri L., Murray, Susan F., Gaus, Hans, Crosby, Jeff, Lima, Walt F., Guo, Shuling, Monia, Brett P., Swayze, Eric E., Seth, Punit P.
Publicado 2014